GLP-1 Tapering & Weaning Schedule Calculator
Calculate a clinically structured step-down titration or injection interval stretching schedule when weaning off Mounjaro, Zepbound, Ozempic, or Wegovy.
Clinical arithmetic and trial reference, not a medical prescription. Tapering, interval stretching, or discontinuing a GLP-1 or GIP/GLP-1 receptor agonist alters metabolic regulation, blood glucose, and gastric motility. Dose alterations or cessation should always be designed and monitored in collaboration with your prescribing healthcare provider, particularly if prescribed for type 2 diabetes or cardiovascular risk reduction.
Stopping a GLP-1 medication abruptly ("cold turkey") triggers a rapid rebound in appetite, food noise, and gastric emptying speed within 10 to 21 days. In clinical trial extensions (STEP-1 for semaglutide, SURMOUNT-4 for tirzepatide), patients discontinuing without a structured maintenance protocol regained approximately two-thirds (66%) of lost weight within 12 months. A structured step-down titration (reducing dose by one step every 2–4 weeks) or interval stretching (spacing shots from 7 to 10 or 14 days) allows the gut-brain axis to adapt gradually while you establish permanent nutritional and resistance-training baselines.
Tirzepatide half-life: ~5 days. Semaglutide half-life: ~7 days.
The dose you are taking right now.
Step-down lowers weekly dose; interval stretching extends shot intervals.
4 weeks matches full pharmacokinetic steady-state equilibration.
Log custom injection intervals (7, 10, or 14 days), monitor estimated active peptide levels as they drop, and record weekly rolling weight averages offline. 100% private on iPhone.
Your Step-by-Step Schedule & Clinical Milestones
Adjusted dynamically based on your starting dose and weaning pace. Each phase represents an equilibrium period for hunger hormones:
| Timeline | Scheduled Dose | Injection Frequency | Relative Level | Clinical Milestones & Nutritional Focus |
|---|
Why Doctors Recommend Tapering Over Cold Turkey
GLP-1 receptor agonists (semaglutide) and dual GIP/GLP-1 agonists (tirzepatide) exert profound regulatory control over four biological systems:
- Gastric Emptying: Slows stomach motility so food remains in the digestive tract significantly longer, signaling fullness.
- Hypothalamic Appetite Regulation: Suppresses central hunger signaling and quiets obsessive food thoughts ("food noise").
- Insulin & Glucagon Secretion: Enhances glucose-dependent insulin release while blunting postprandial glucagon surges.
- Reward Center Dopaminergic Modulation: Dampens hedonic cravings for ultra-processed, hyper-palatable foods.
When medication is stopped abruptly, the biological brake is released before your body's natural satiety mechanisms recalibrate. Circulating active levels drop over 3 to 5 weeks, but hunger hormones (particularly ghrelin) surge above baseline, often triggering severe rebound overeating. A gradual taper allows the digestive system and central nervous system to readapt step by step.
The Three Main Weaning Approaches Compared
| Protocol | How It Works | Best Suited For | Key Advantage |
|---|---|---|---|
| Step-Down Titration | Reduce your weekly dose by one official step every 2 to 4 weeks (e.g. 15 → 12.5 → 10 → 7.5 → 5 → 2.5 mg). | Patients at high or maximum doses wanting to discontinue safely. | Maintains consistent once-weekly injection routine with no calendar confusion. |
| Interval Stretching | Keep your current or intermediate dose, but expand injection spacing from every 7 days to every 9, 10, 14, or 21 days. | Patients with stable satiety who want to reduce cost or ease off slowly. | Cuts monthly medication costs by 30%–50% while maintaining trough baseline receptor coverage. |
| Threshold Maintenance | Step down to the lowest therapeutic threshold (2.5 mg tirzepatide or 0.25–0.5 mg semaglutide) indefinitely. | Individuals with chronic metabolic resistance, severe pre-treatment obesity, or diabetes. | Highest long-term weight stability; prevents the 66% regain documented in clinical trials. |
The 4 Golden Rules During a GLP-1 Taper
- Track a 7-day rolling weight average, never daily spikes: As gastric emptying accelerates, the volume of digestive matter and glycogen-bound water increases by 2 to 4 pounds in the first 2 weeks. This is water and digestive bulk, not body fat.
- Target 0.7 to 1.0 grams of protein per pound of lean body mass: Higher protein intake stimulates endogenous peptide YY (PYY) and cholecystokinin (CCK) release, replacing artificial satiety with natural biological satiety.
- Preserve resistance training: Lifting weights 2 to 3 times per week preserves metabolic rate and muscle mass, reducing the drop in resting daily calorie burn.
- Log hunger & food noise severity: Note when cravings return. If food noise reaches pre-treatment intensity during a step-down, pause at that step for an additional 4 weeks before reducing further.
Related Transition Guides & Tools
Common Questions About Weaning Off GLP-1s
- Can I just stop Mounjaro or Ozempic cold turkey?
- While stopping cold turkey does not cause physical drug withdrawal like opioids or alcohol, it causes rapid rebound hunger and intense food noise within 2 to 3 weeks as the medication clears. Studies show patients who stop abruptly regain approximately two-thirds of their lost weight within a year. A structured taper significantly eases this transition.
- How does interval stretching (spacing doses 10 to 14 days apart) work?
- Because tirzepatide has a 5-day half-life and semaglutide has a 7-day half-life, spacing injections to every 10 or 14 days allows the drug blood concentration to drop lower during the trough while still blunting severe hunger spikes. It is an effective way to test whether your endogenous satiety cues can sustain weight stability with minimal drug support.
- What if my hunger returns fiercely during a dose step-down?
- If uncontrollable hunger or binge urges recur when stepping down (e.g. from 10 mg to 7.5 mg), clinical consensus is to hold at your current step for an extra 4 weeks or return to the prior dose. Many patients discover their minimum effective maintenance threshold (often 5.0 mg for tirzepatide or 0.5 mg for semaglutide) and choose to stay there long term.
- How long does it take for the medication to completely leave my system?
- It takes approximately 4 to 5 half-lives for a drug to reach <3% circulating concentration. For tirzepatide (~5 day half-life), clearance takes roughly 25 days. For semaglutide (~7 day half-life), clearance takes roughly 35 days.
Want this tracked for you?
GLPme logs every shot, remembers your titration schedule, warns you before you run out of medication, and shows your weight trend against your goal. Core tracking is free.
⚡ 100% Private on-device logging · Free on iOS